Questions About Fugitive Aerosols: The Answer Is PPE

References

1. 1.↵
   1. Ferioli M,
   2. Cisternino C,
   3. Leo V,
   4. Pisani L,
   5. Palange P,
   6. Nava S

   . Protecting health care workers from SARS-CoV-2 infection: practical indications. Eur Respir Rev 2020;29(155):200068.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Tran K,
   2. Cimon K,
   3. Severn M,
   4. Pessoa-Silva CL,
   5. Conly J

   . Aerosol-generating procedures and risk of transmission of acute respiratory infections to health care workers: a systematic review. PLoS One 2012;7(4):e35797.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Seto WH,
   2. Tsang D,
   3. Yung RW,
   4. Ching TY,
   5. Ng TK,
   6. Ho M,
   7. et al

   . Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet 2003;361(9368):1519-1520.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Gomersall CD,
   2. Joynt GM,
   3. Ho OM,
   4. Ip M,
   5. Yap F,
   6. Derrick JL,
   7. et al

   . Transmission of SARS to health care workers. The experience of a Hong Kong ICU. Intensive Care Med 2006;32(4):564-569.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Chan VW,
   2. Ng HH,
   3. Rahman L,
   4. Tang A,
   5. Tang KP,
   6. Mok A,
   7. et al

   . Transmission of severe acute respiratory syndrome coronavirus 1 and severe acute respiratory syndrome coronavirus 2 during aerosol-generating procedures in critical care: a systematic review and meta-analysis of observational studies. Crit Care Med 2021;49(7):1159-1168.

   OpenUrl
6. 6.↵
   1. Klompas M,
   2. Baker M,
   3. Rhee C

   . What Is an aerosol-generating procedure? JAMA Surg 2021;156(2):113-114.

   OpenUrlPubMed
7. 7.↵
   1. Fink JB,
   2. Ehrmann S,
   3. Li J,
   4. Dailey P,
   5. McKiernan P,
   6. Darquenne C,
   7. et al

   . Reducing aerosol-related risk of transmission in the era of COVID-19: an interim guidance endorsed by the International Society of Aerosols in Medicine. J Aerosol Med Pulm Drug Deliv 2020;33(6):300-304.

   OpenUrlPubMed
8. 8.↵
   1. Jermy MC,
   2. Spence CJT,
   3. Kirton R,
   4. O’Donnell JF,
   5. Kabaliuk N,
   6. Gaw S,
   7. et al

   . Assessment of dispersion of airborne particles of oral/nasal fluid by high-flow nasal cannula therapy. PLoS One 2021;16(2):e0246123.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Cazzola M,
   2. Ora J,
   3. Bianco A,
   4. Rogliani P,
   5. Matera MG

   . Guidance on nebulization during the current COVID-19 pandemic. Respir Med 2021;176:106236.

   OpenUrl
10. 10.↵
    1. Sethi S,
    2. Barjaktarevic IZ,
    3. Tashkin DP

    . The use of nebulized pharmacotherapies during the COVID-19 pandemic. Ther Adv Respir Dis 2020;14:1753466620954366.

    OpenUrl
11. 11.↵
    1. Goldstein KM,
    2. Ghadimi K,
    3. Mystakelis H,
    4. Kong Y,
    5. Meng T,
    6. Cantrell S,
    7. et al

    . Risk of transmitting coronavirus disease 2019 during nebulizer treatment: a systematic review. J Aerosol Med Pulm Drug Deliv 2021;34(3):155-170.

    OpenUrl
12. 12.↵
    1. Li J,
    2. Fink JB

    . Narrative review of practical aspects of aerosol delivery via high-flow nasal cannula. Ann Transl Med 2021;9(7):590.

    OpenUrl
13. 13.↵
    1. McGrath JA,
    2. O’Toole C,
    3. Bennett G,
    4. Joyce M,
    5. Byrne MA,
    6. MacLoughlin R

    . Investigation of fugitive aerosols released into the environment during high-flow therapy. Pharmaceutics 2019;11(6):254.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Harnois L,
    2. Alolaiwat A,
    3. Jing G,
    4. Fink JB,
    5. Dhand R,
    6. Li J

    . Efficacy of various mitigation devices in reducing fugitive emissions from nebulizers. Respir Care 2021;67(4):394-403.

    OpenUrl
15. 15.↵
    1. Li J,
    2. Alolaiwat A,
    3. Harnois L,
    4. Fink JB,
    5. Dhand R

    . Mitigating fugitive aerosols during aerosol delivery via high-flow nasal cannula devices. Respir Care 2021;67(4):404-414.

    OpenUrl
16. 16.↵
    1. Villarreal-Fernandez E,
    2. Patel R,
    3. Golamari R,
    4. Khalid M,
    5. DeWaters A,
    6. Haouzi P

    . A plea for avoiding systematic intubation in severely hypoxemic patients with COVID-19–associated respiratory failure. Crit Care 2020;24(1):337.

    OpenUrl
17. 17.↵
    1. Lee YH,
    2. Choi KJ,
    3. Choi SH,
    4. Lee SY,
    5. Kim KC,
    6. Kim EJ

    . Clinical significance of timing of intubation in critically ill patients with COVID-19: a multi-center retrospective study. J Clin Med 2020;9(9).
18. 18.↵
    1. Mellado-Artigas R,
    2. Ferreyro BL,
    3. Angriman F,
    4. Hernandez-Sanz M,
    5. Arruti E,
    6. Torres A,
    7. et al

    ; COVID-19 Spanish ICU Network. High-flow nasal oxygen in patients with COVID-19–associated acute respiratory failure. Crit Care 2021;25(1):58.

    OpenUrlPubMed
19. 19.↵
    1. Papoutsi E,
    2. Giannakoulis VG,
    3. Xourgia E,
    4. Routsi C,
    5. Kotanidou A,
    6. Siempos II

    . Effect of timing of intubation on clinical outcomes of critically ill patients with COVID-19: a systematic review and meta-analysis of nonrandomized cohort studies. Crit Care 2021;25(1):121.

    OpenUrl
20. 20.↵
    1. Tashkin DP,
    2. Barjaktarevic IZ

    . Nebulized treatments and the possible risk of coronavirus transmission: where is the evidence? Chronic Obstr Pulm Dis 2020;7(3):136-138.

    OpenUrl
21. 21.↵
    1. Li J,
    2. Fink JB,
    3. Elshafei AA,
    4. Stewart LM,
    5. Barbian HJ,
    6. Mirza SH,
    7. et al

    . Placing a mask on COVID-19 patients during high-flow nasal cannula therapy reduces aerosol particle dispersion. ERJ Open Res 2021;7(1):00519-2020.
22. 22.↵
    1. Wallin M,
    2. Tang P,
    3. Chang RYK,
    4. Yang M,
    5. Finlay WH,
    6. Chan HK

    . Aerosol drug delivery to the lungs during nasal high-flow therapy: an in vitro study. BMC Pulm Med 2019;19(1):42.

    OpenUrl
23. 23.↵
    1. Myers TR

    . The science guiding selection of an aerosol delivery device. Respir Care 2013;58(11):1963-1973.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Nishimura M

    . High-flow nasal cannula oxygen therapy in adults: physiological benefits, indication, clinical benefits, and adverse effects. Respir Care 2016;61(4):529-541.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Ospina-Tascon GA,
    2. Calderon-Tapia LE,
    3. Garcia AF,
    4. Zarama V,
    5. Gomez-Alvarez F,
    6. Alvarez-Saa T,
    7. et al

    ; HiFLo-Covid Investigators. Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: a randomized clinical trial. JAMA 2021;326(21):2161-2171.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Bennett G,
    2. Joyce M,
    3. Fernandez EF,
    4. MacLoughlin R

    . Comparison of aerosol delivery across combinations of drug delivery interfaces with and without concurrent high-flow nasal therapy. Intensive Care Med Exp 2019;7(1):20.

    OpenUrl
27. 27.↵
    1. Montiel V,
    2. Robert A,
    3. Robert A,
    4. Nabaoui A,
    5. Marie T,
    6. Mestre NM,
    7. et al

    . Surgical mask on top of high-flow nasal cannula improves oxygenation in critically ill COVID-19 patients with hypoxemic respiratory failure. Ann Intensive Care 2020;10(1):125.

    OpenUrl
28. 28.↵
    1. Jin YH,
    2. Huang Q,
    3. Wang YY,
    4. Zeng XT,
    5. Luo LS,
    6. Pan ZY,
    7. et al

    . Perceived infection transmission routes, infection control practices, psychosocial changes, and management of COVID-19–infected health care workers in a tertiary acute care hospital in Wuhan: a cross-sectional survey. Mil Med Res 2020;7(1):24.

    OpenUrlCrossRefPubMed